The Competition Board concluded the preliminary inquiry conducted in response to the claims that Novartis Sağlık Gıda ve Tarım Ürünleri San. ve Tic. A.Ş., abused its dominant position by refusing to deal with the complainant and distorted competition at wholesale level in the pharmaceutical sector by preventing pharmaceutical warehouses that it works with from making sales to other pharmaceutical warehouses.

After discussing the information and documents acquired and observations made in the preliminary inquiry in its meeting of 21.06.2018, the Board concluded that the findings were significant and sufficient, and took the decision no 18-20/349-M to initiate an investigation about:

-    Novartis Sağlık Gıda ve Tarım Ürünleri San. ve Tic. A.Ş. 

-    Alcon Laboratuvarları Ticaret A.Ş.

*Investigation decisions taken by the Competition Board are announced to the public following the notification of the decision to the undertakings or associations of undertakings under investigation. Those announcements, which are made within the framework of informing the public about the decisions of the Competition Board, cannot be interpreted to mean that the undertakings or associations of undertakings under investigation have violated the Act no 4054, or they are or will be subject to penal sanctions under the Act.